A 2-day-old preterm neonatal female (32 weeks gestation) with suspected ABO incompatibility and rising unconjugated hyperbilirubinemia is started on phototherapy. The serum bilirubin level is 16 mg/dL and continues to rise despite 18 hours of intensive phototherapy. Direct antiglobulin test (DAT/Coombs) is positive. What is the drug of choice to be administered immediately?

## Clinical Scenario Analysis This preterm neonate has **confirmed hemolytic disease (positive DAT)** with **severe, rapidly rising hyperbilirubinemia unresponsive to phototherapy** — a critical situation requiring immediate pharmacotherapy to prevent kernicterus. ## Why IVIG is the Correct Choice **Key Point:** IVIG is the **first-line adjunctive pharmacotherapy** for hemolytic disease with severe hyperbilirubinemia in neonates. It must be given **immediately** while preparing for exchange transfusion if needed. **Mechanism of Action:** 1. Binds to Fc receptors on reticuloendothelial macrophages 2. Blocks antibody-mediated hemolysis of sensitized RBCs 3. Reduces the rate of bilirubin production 4. Decreases the need for exchange transfusion by ~50% when given early **Dosing & Administration:** - **Dose:** 0.5–1 g/kg IV infusion - **Rate:** Infuse over 2–4 hours - **Timing:** Administer as soon as hemolytic disease is confirmed and phototherapy fails **High-Yield:** IVIG is most effective in: - **Rh incompatibility** (Rh-negative mother, Rh-positive infant) - **ABO incompatibility** (Group O mother, Group A or B infant) ← **This case** - **G6PD deficiency** with hemolysis **Clinical Pearl:** In preterm infants (like this 32-week neonate), the risk of bilirubin encephalopathy is **higher** at lower bilirubin levels due to immature blood–brain barrier and reduced albumin binding capacity. Early IVIG is therefore even more critical. ## Why Exchange Transfusion Alone Is Not Sufficient **Warning:** Exchange transfusion removes bilirubin acutely but does NOT stop ongoing hemolysis. Without IVIG, bilirubin will rebound rapidly post-transfusion. **IVIG + phototherapy + exchange transfusion (if threshold reached) is the complete strategy.** ## Comparison of Management Strategies | Intervention | Mechanism | Timing | Role | |--------------|-----------|--------|------| | **IVIG** | Blocks Fc receptors; stops hemolysis | Immediate (within 24 hrs of phototherapy failure) | **First-line adjunct** | | **Phototherapy** | Converts unconjugated bilirubin to water-soluble isomers | Continuous | Foundation of treatment | | **Exchange transfusion** | Removes bilirubin & sensitized RBCs | When bilirubin exceeds threshold | **Definitive** if IVIG + phototherapy fail | | **Albumin** | Increases bilirubin binding capacity | Adjunct in severe cases | **Not primary therapy**; use if albumin <2.5 g/dL | | **Calcium gluconate** | Prevents hypocalcemia from citrate in transfused blood | During/after exchange transfusion | **Not for hyperbilirubinemia per se** | ## Treatment Algorithm for Hemolytic Hyperbilirubinemia ```mermaid flowchart TD A["Hemolytic disease confirmed<br/>(positive DAT + rising bilirubin)"]:::outcome --> B["Start intensive phototherapy"]:::action B --> C["Administer IVIG 0.5-1 g/kg IV"]:::action C --> D{"Bilirubin response<br/>in 6-12 hours?"}:::decision D -->|"Declining"| E["Continue phototherapy<br/>Repeat bilirubin q4-6h"]:::action D -->|"Still rising or<br/>at/above threshold"| F["Prepare for exchange transfusion"]:::urgent F --> G["Perform double-volume exchange transfusion"]:::action G --> H["Restart phototherapy post-transfusion"]:::action H --> I["Monitor for rebound hyperbilirubinemia"]:::action ``` **Key Point:** IVIG must be given **before or concurrent with** exchange transfusion preparation to maximize the chance of avoiding transfusion altogether. [cite:Nelson Textbook of Pediatrics 21e Ch 102; AAP Phototherapy and Jaundice Management Guidelines 2009]